ClinicalTrials.gg
Active, not recruitingNCT06842823ALPHA-ORBITUpdated Jun 30, 2026

A Study of Navenibart in Participants With Hereditary Angioedema

A Phase 3 interventional study of navenibart and Placebo in Hereditary Angioedema (HAE), sponsored by Astria Therapeutics, Inc.. Active, not recruiting at 86 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Astria Therapeutics, Inc. (part of BioCryst Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.

Enrollment
2nd of 21
157 · median 54
Started
2025
with 1 other
Phase 3
7 of 22
2 open now
Registered
21st of 22
by date

Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 3, and was the 21st registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, or all of them as a file.
02

Study summary

This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • HAE
  • Angioedema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of HAE (Type 1 or 2). The following must be met:

    1. Documented clinical history consistent with HAE
    2. Lab findings consistent with HAE Type 1 or 2
  • Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack.

Exclusion criteria

Exclusion Criteria:

  • Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathic angioedema, or angioedema associated with urticaria.
  • Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to prior to entering the Run-In Period).

    1. Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3 days prior to Run-In
    2. Plasma-derived C1INH for LTP within 14 days prior to Run-In
    3. Berotralstat within 21 days prior to Run-In
    4. Lanadelumab within 70 days prior to Run-In
    5. Garadacimab within 90 days prior to Run-In
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Adult Navenibart Dosing Regimen 1

    Participants will receive 600 mg of navenibart every 3 months.

    Drug: navenibart

  • Experimental
    Adult Navenibart Dosing Regimen 2

    Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.

    Drug: navenibart

  • Experimental
    Adult Navenibart Dosing Regimen 3

    Participants will receive 600 mg of navenibart every 6 months.

    Drug: navenibart

  • Placebo comparator
    Placebo (adult)

    Participants will receive placebo every 3 months.

    Drug: Placebo

  • Experimental
    Adolescent Navenibart Dosing Regimen 1

    Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.

    Drug: navenibart

Interventions

  • Navenibart will be administered as a subcutaneous injection.

    Also known as: STAR-0215

  • DrugPlacebo

    Placebo will be administered as a subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period.

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Number of moderate or severe investigator-confirmed HAE attacks during the 6-month Treatment Period.

    Time frame: Day 1 through Day 181

  2. Number of investigator-confirmed HAE attacks that require on-demand treatment during the 6-month Treatment Period.

    Time frame: Day 1 through Day 181

  3. Percent reduction in monthly investigator-confirmed HAE attacks in the 6-month Treatment Period versus the Run-In Period.

    Time frame: Baseline through Day 181

  4. Time to first investigator-confirmed HAE attack after first and second dose.

    Time frame: Day 1 through Day 181

  5. The number of participants responding to treatment, defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from the Run-In Period in investigator-confirmed HAE attack rate (for adult participants: compared to placebo during the 6-month Treatment Period).

    Time frame: Baseline through Day 181

  6. Number of participants with no investigator-confirmed HAE attacks during the 6-month Treatment Period.

    Time frame: Day 1 through Day 181

  7. Change from baseline (Day 1) in the Angioedema Quality of Life questionnaire total score.

    Time frame: Day 1 through Day 181

Other outcomes

  1. Incidence of treatment-emergent adverse events.

    Time frame: Day 1 through Day 361

07

Study locations

86 sites
  • Site 9
    Birmingham, Alabama 35209, United States
  • Site 2
    Scottsdale, Arizona 85251, United States
  • Site 3
    Little Rock, Arkansas 72205, United States
  • Site 26
    San Diego, California 92122, United States
  • Site 14
    San Diego, California 92123,, United States
  • Site 4
    Santa Monica, California 90404, United States
  • Site 1
    Walnut Creek, California 94598, United States
  • Site 8
    Centennial, Colorado 80112, United States
  • Site 11
    Colorado Springs, Colorado 80907, United States
  • Site 25
    Tampa, Florida 33613, United States
  • Site 69
    Weston, Florida 33331, United States
  • Site 6
    Wheaton, Maryland 20902, United States
  • Site 67
    Boston, Massachusetts 02114, United States
  • Site 13
    Detroit, Michigan 48202, United States
  • Site 10
    St Louis, Missouri 63141, United States
  • Site 7
    Cincinnati, Ohio 45236, United States
  • Site 12
    Toledo, Ohio 43617, United States
  • Site 15
    Hummelstown, Pennsylvania 17036, United States
  • Site 86
    Dallas, Texas 75231, United States
  • Site 68
    Campbelltown, New South Wales 2560, Australia
  • Site 76
    Melbourne, Victoria, Australia
  • Site 74
    Murdoch, WA 6150, Australia
  • Site 83
    Vienna, 1090, Austria
  • Site 45
    Santo André, 09060870, Brazil
  • Site 28
    Sofia, 1680, Bulgaria
  • Site 5
    Ottawa, Ontario K1H 1E4, Canada
  • Site 23
    Edmonton, AB T6G 2B7, Canada
  • Site 37
    Hradec Králové, 500 05, Czechia
  • Site 39
    Prague, 150 06, Czechia
  • Site 46
    La Tronche, 38700, France
  • Site 54
    Lille, 59037, France
  • Site 65
    Marseille, 13005, France
  • Site 72
    Nice, 06202, France
  • Site 52
    Paris, 75012, France
  • Site 38
    Berlin, 12203, Germany
  • Site 44
    Frankfurt, D-60590, Germany
  • Site 70
    Hanover, 30625, Germany
  • Site 20
    Hong Kong, Hong Kong
  • Site 64
    Budapest, 1088, Hungary
  • Site 55
    Ashkelon, 7830604, Israel
  • Site 49
    Haifa, 3104802, Israel
  • Site 35
    Petah Tikva, 49100, Israel
  • Site 34
    Petah Tikva, 4920235, Israel
  • Site 53
    Tel Aviv, 6423906, Israel
  • Site 42
    Milan, 20138, Italy
  • Site 85
    Milan, 20157, Italy
  • Site 51
    Monserrato, 09042, Italy
  • Site 51
    Monserrato, CA 09042, Italy
  • Site 66
    Padova, 35128, Italy
  • Site 40
    San Donato Milanese, 20097, Italy
  • Site 41
    Torino, 10128, Italy
  • Site 30
    Fukuoka, Kurume-shi 830-0011, Japan
  • Site 56
    Tsu, Mei 514-8507, Japan
  • Site 61
    Kawagoe, Saitama 350-8550, Japan
  • Site 31
    Saitama, Soka-shi 340-0041, Japan
  • Site 57
    Hiroshima, 730-8518, Japan
  • Site 50
    Hiroshima, 734-8551, Japan
  • Site 58
    Kawasaki, 216-8511, Japan
  • Site 80
    Nagasaki, 852-8501, Japan
  • Site 47
    Saga, 849-8501, Japan
  • Site 73
    Tokyo, 173-0032, Japan
  • Site 27
    Amsterdam, Netherlands
  • Site 75
    Auckland, New Zealand
  • Site 33
    Skopje, 1000, North Macedonia
  • Site 71
    Krakow, 31-503, Poland
  • Site 78
    Lodz, 92-213, Poland
  • Site 29
    Rzeszów, 35-051, Poland
  • Site 79
    Warsaw, 04-141, Poland
  • Site 81
    Coimbra, 3004-561, Portugal
  • Site 82
    Lisbon, 1649-028, Portugal
  • Site 59
    San Juan, 00918, Puerto Rico
  • Site 21
    Cape Town, 7700, South Africa
  • Site 62
    Seoul, Jongno, South Korea
  • Site 60
    Yangcheon, Seoul, South Korea
  • Site 77
    Seongnam-si, South Korea
  • Site 32
    Barcelona, Spain
  • Site 63
    Madrid, 28007, Spain
  • Site 84
    Santa Cruz de Tenerife, 38010, Spain
  • Site 48
    Seville, 41013, Spain
  • Site 36
    Valencia, 46026, Spain
  • Site 18
    Plymouth, Devon PL6 8HD, United Kingdom
  • Site 24
    Hampstead, London NW3 2QG, United Kingdom
  • Site 19
    Bristol, BS10 5N, United Kingdom
  • Site 16
    Cambridge, CB2 0QQ, United Kingdom
  • Site 22
    Frimley, GU16 7UJ, United Kingdom
  • Site 17
    London, E1 2ES, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 21 months is close to that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 24, 2025
StartActual
Mar 20, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06842823
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 20, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navenibart

Start the discussion